Dr. Neil Mukund Iyengar, MD

Dr. Iyengar practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Iyengar's NPI, 1194987230, was assigned on June 30, 2008. Dr. Iyengar graduated from University of Illinois College of Medicine at Chicago in 2008. Dr. Iyengar holds New York license 260648-1.

Dr. Iyengar's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Iyengar's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Iyengar is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Iyengar to 1 more hospital, 2 medical groups, 1 clinical lab and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iyengar practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Iyengar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Iyengar's licenses on file in 2 states: New York and Illinois.

CMS data shows 142 Medicare services from Dr. Iyengar across 3 procedure codes in 2024, all of them office visits, for 96 Medicare patients. Medicare paid $13,940 for them. Every service was in an office.

CMS counts 96 Medicare patients who saw Dr. Iyengar in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have cancer, and 70% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Iyengar's median patient age at 69, with 86% women.

In 2024, Dr. Iyengar wrote 156 Medicare Part D claims for 57 patients. 89% of them were for generic drugs. CMS names the drug for 110 of them, across 2 drugs with 11 or more claims each, at $1,872 in total drug cost. In 2023, CMS named 92 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Iyengar for performance year 2024, reported as part of a group. Dr. Iyengar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 74 papers to Dr. Iyengar, published from 2013 to 2025. 2018 was the busiest year, with 7. The most frequent topics are Breast Neoplasms, Obesity and Inflammation. Dr. Iyengar has published most often in Cancer. Dr. Iyengar's most frequent co-authors are Patrick G. Morris, MD, Dilip D. Giri, MD and Clifford A. Hudis, MD.

Dmand AI links Dr. Iyengar to 6 clinical trials, 2 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Motor Activity and Behavior. Memorial Sloan Kettering Cancer Center sponsors the most, 6.

CMS Open Payments shows 338 general payments to Dr. Iyengar from 15 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 46% of the total. Pfizer Inc. paid the most, $142,119. It also lists 6 research payments totaling $7,726 from 2021 to 2025.

Dr. Iyengar graduated from University of Illinois College of Medicine at Chicago in 2008.